Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review.
about
Thrombocytopenia and hemostatic disorders in chronic graft versus host disease.Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipientsCytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trialInfections in liver transplant recipients.Effects of donor/recipient human leukocyte antigen mismatch on human cytomegalovirus replication following liver transplantationRetrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir and oral valganciclovir.Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy.Immune response to CMV in solid organ transplant recipients: current concepts and future directions.Cytomegalovirus infection in liver transplant recipients: updates on clinical managementEfficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis.Cytomegalovirus Infection in Pediatric Solid Organ Transplant Recipients: a Focus on Prevention.Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update.Differentiation between polymorphisms and resistance-associated mutations in human cytomegalovirus DNA polymerase.Two-year post-transplantation cytomegalovirus DNAemia in asymptomatic kidney transplant recipients: incidence, risk factors, and outcome.Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients.Biliary complications after liver transplantation.Detection of Two Drug-Resistance Mutants of the Cytomegalovirus by High-Resolution Melting Analysis.Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): experience from the RESITRA-REIPI cohort.Does the calcineurin inhibitor have influence on cytomegalovirus infection in heart transplantation?Cytomegalovirus prophylaxis in pediatric kidney transplantation: the Dutch experience.Repeated CMV infection in a heart transplantation patient.Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation.Kidney transplantation in the United States: economic burden and recent trends analysis.Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.The effect of sirolimus-based immunosuppression vs. conventional prophylaxis therapy on cytomegalovirus infection after liver transplantation.Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study.Genotyping cytomegalovirus UL97 mutations by high-resolution melting analysis with unlabeled probe.Cost analysis in favor of a combined approach for cytomegalovirus after kidney transplantation: a single-center experience
P2860
Q33385836-09C7536A-3E8E-4585-B6F7-0BD60565AB80Q33932079-55D785F9-DF59-4FD6-9B7A-77B8C7147508Q34786700-A0C5674C-1621-4263-A472-D1AF741F1C3FQ34993661-FE5D86BE-E7F4-4F18-99AF-BB4A0221ED8CQ35134243-4DC33C76-5AE0-42EF-B199-0BDFCA3E3770Q35785403-95A440B4-DC6D-4015-AC8E-E2C990F695D0Q37965695-F0C83743-6E83-436F-AF40-57AD0515921AQ38011227-B3F2E4F4-152D-46A7-A39A-E07E6E770AB9Q38242802-B96FF690-71B7-4013-B01D-78E64FAC2E92Q38364698-195EE6DC-5035-4958-8E56-17D96B4EFB6CQ38689823-96D58355-6D58-4ECC-9599-BD050238AE87Q38875887-CC30264F-3705-43CA-AEEA-C67E40F18488Q39650785-B248B0B5-66C3-431B-9CB7-4C9C27D3CBE1Q41177320-801E794A-C48D-40E2-BB0F-8555206C6D89Q41439136-C51F0964-88B3-4621-8C0B-BE0E54D578E4Q41694479-3913E0FB-1CB4-4999-AFF7-8E8A149CF268Q41742346-0A35147D-EBA3-4586-8A9D-1D3173091FB3Q42216221-9B5BF5FB-6AC3-455F-9B3F-39E712940EB5Q42249961-10AE14B2-291E-46AE-8AEA-7E1B8208E143Q42281180-D30782F0-7833-4D69-808B-4B82C50FE17BQ42352189-24ACCC72-F0D9-4D13-B86D-B742B1B62BC5Q43523397-21840EAF-6D00-4CBC-BA11-375032DC14DFQ43640660-E35828FE-D7F3-4A94-905D-7CD1BDFF4783Q44100013-078C5D9F-B30F-4122-86CA-81B2228C15F8Q50569364-27F29181-1873-4AB8-A734-6B9A69D8C42BQ52728252-0036EA84-248A-472D-8DA5-00EDDE549D98Q54540115-D3253322-DF04-480C-90A3-8C1D48219E53Q57515316-1CAACA44-94BD-44BA-8EDF-3236F1EE4735
P2860
Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prevention of posttransplant c ...... ciclovir: a systematic review.
@en
Prevention of posttransplant c ...... ciclovir: a systematic review.
@nl
type
label
Prevention of posttransplant c ...... ciclovir: a systematic review.
@en
Prevention of posttransplant c ...... ciclovir: a systematic review.
@nl
prefLabel
Prevention of posttransplant c ...... ciclovir: a systematic review.
@en
Prevention of posttransplant c ...... ciclovir: a systematic review.
@nl
P2093
P1476
Prevention of posttransplant c ...... ciclovir: a systematic review.
@en
P2093
P304
P356
10.1111/J.1600-6143.2008.02369.X
P407
P577
2008-10-01T00:00:00Z